Allgenesis Receives Notice of Grant of Japanese Patent for anti-VEGF/Disintegrin Fusion Protein

Allgenesis: Final Database Lock Reaffirms Excellent Safety, Tolerability, and Signs of Efficacy from POC Phase 2a Study of AG-86893 in Patients with Pterygium
Dr. Sunil Patel Joins Allgenesis’ Scientific Advisory Board
Show all

Taipei, Taiwan/ February 4th, 2020

Allgenesis Biotherapeutics Inc., a Taiwan based specialty pharmaceutical company focused on developing novel ophthalmic drugs, announced today that the Japan Patent Office (JPO) has issued a Notice of Grant for a Patent covering Allgenesis’ second biologic product, AG-73305, a first-in-class drug that fuses an anti-VEGF domain (clinically validated target) and a disintegrin domain into one molecule. AG-73305 simultaneously binds to multiple targets which are known to be involved in retinal diseases, and has the potential to treat anti-VEGF responders and non-responders.

“It is proven to be safe and efficacious in our animal studies. Having this patent granted in Japan would provide asset value for Japanese Pharma Companies or business partners interested in collaborating with Allgenesis on our novel protein for treating retinal diseases,” said Dr. Madhu Cherukury, Chief Executive Officer of Allgenesis. “Since VEGF is a clinically validated target for the treatment of various retinal diseases and the disintegrin domain has been found to also inhibit angiogenesis, a fusion of both molecules can effectively target various angiogenic diseases, particularly those in ophthalmology. We are expecting more patent grants to build protections for a global market in the coming years.”

The newly issued patent provides coverage of the fusion protein and its use to treat angiogenic diseases, such as wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) in Japan up to the year 2036.

About Allgenesis

Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases, AG-86893 for pterygium, and AG-67650 for wAMD.

About AG-73305

AG-73305 is a first-in-class molecule specifically designed for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is a single fusion protein that simultaneously binds with high potency and specificity to VEGF and integrins, which are known to be involved in retinal diseases. AG-73305 has the potential to treat anti-VEGF responders and non-responders.